Edward Garon, MD, Oncology, Santa Monica, CA, Ronald Reagan UCLA Medical Center

EdwardBrianGaronMD

Oncology Santa Monica, CA

Hematologic Oncology

Assistant Professor, Medicine, UCLA School of Medicine

Dr. Garon is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Garon's full profile

Already have an account?

Education & Training

  • UCLA Medical Center
    UCLA Medical CenterFellowship, Hematology/Oncology, 2003 - 2006
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 1999 - 2002
  • Washington University School of Medicine in St. Louis
    Washington University School of Medicine in St. LouisClass of 1999

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2003 - 2022
  • IL State Medical License
    IL State Medical License 1999 - 2005
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer  
    Edward B Garon, Maeve Waldron-Lynch, The New England Journal of Medicine

Lectures

  • Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
  • Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • New Lung Cancer Treatments Lead to Vastly Improved Survival Rates
    New Lung Cancer Treatments Lead to Vastly Improved Survival RatesNovember 6th, 2020
  • Lilly's CYRAMZA® (Ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in the Lancet Oncology
    Lilly's CYRAMZA® (Ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in the Lancet OncologyDecember 13th, 2019
  • Ramucirumab, Erlotinib Combo a Promising First-Line EGFR-Mutated NSCLC Treatment
    Ramucirumab, Erlotinib Combo a Promising First-Line EGFR-Mutated NSCLC TreatmentOctober 9th, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations